BioWorld

July 28, 2009

Avila Raises $30M, Pulls Down $200M Deal with Novartis Fund

Biotech start-up Avila Therapeutics Inc. not only raised $30 million in a Series B financing, but snagged a deal potentially worth $200 million in up-front and milestones plus royalties with Novartis Option Fund. (BioWorld Today) Read More

Cerulean Steps Up 'Tempo,' Gets $10M for Nanoparticles

GSK Deal, Strong Quarter Get Amgen High Wall Street Marks

Liraglutide's Good-Data Ride: A Higher Bar for Byetta LAR?

More Action in the Tools Space: Agilent Buying Varian for $1.5B

Other News To Note

Clinic Roundup

Today's news in brief

BioWorld

BioWorld briefs for Jan 26, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Jan. 27, 2026.

DNA mutations or genetic disorder concept art

Biallelic variants in COX18 identified as cause of Charcot-Marie-Tooth disease

BioWorld Science

Charcot-Marie-Tooth (CMT) disease is a group of clinically and genetically heterogeneous sensorimotor peripheral neuropathies. It is the most frequent inherited...

Muted and missing M&As: JPM deals absent in 2026

BioWorld

For years, the J.P. Morgan Healthcare Conference (JPM) kicked off with splashy headlines of major M&A activity among biopharma companies, but in 2026, the hype...

Brain-derived tau in blood predicts stroke severity and outcome

BioWorld Science

Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...